Can a radioactive compound outsmart resistant neuroblastoma?
NCT ID NCT07767630
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This early-phase trial is exploring whether a radioactive drug called [211At]MABG, given in several smaller doses, is safe and tolerable for children with neuroblastoma that has relapsed or not responded to treatment. The study will include about 10 participants aged 1 year and older whose tumors show MIBG uptake. Researchers will monitor side effects and measure how the radiation distributes in the body, while also looking for signs that the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A radioactive compound called [211At]MABG, given in divided doses to target neuroblastoma cells.
- What this could lead to
- If successful, this could offer a new treatment option for children with neuroblastoma that has returned or not responded to standard therapy.
- What could go wrong
- This is a very early, small study focused on safety. The treatment may cause side effects, and it is too soon to know if it will effectively control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA (NB) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital
RECRUITINGChengdu, Sichuan, 000000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.